152 related articles for article (PubMed ID: 33847134)
1. Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer.
Peng QQ; Li JL; Xin PL; Du KX; Lin XY; Wu JX; Zhang MT; Kong XQ
Neoplasma; 2021 Jul; 68(4):742-750. PubMed ID: 33847134
[TBL] [Abstract][Full Text] [Related]
2. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
[TBL] [Abstract][Full Text] [Related]
3. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
[TBL] [Abstract][Full Text] [Related]
4. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
5. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
[TBL] [Abstract][Full Text] [Related]
6. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
8. Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study.
Abdel-Rahman O; Kumar A; Kennecke HF; Speers CH; Cheung WY
Clin Colorectal Cancer; 2018 Mar; 17(1):e21-e28. PubMed ID: 28709877
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute
Herrmann M; Schulte S; Wildner NH; Wittner M; Brehm TT; Ramharter M; Woost R; Lohse AW; Jacobs T; Schulze Zur Wiesch J
Front Immunol; 2020; 11():1870. PubMed ID: 32983106
[TBL] [Abstract][Full Text] [Related]
10. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
[TBL] [Abstract][Full Text] [Related]
13. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
Ann Oncol; 2017 Dec; 28(12):2977-2984. PubMed ID: 29045526
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.
Mimura K; Kua LF; Xiao JF; Asuncion BR; Nakayama Y; Syn N; Fazreen Z; Soong R; Kono K; Yong WP
Gastric Cancer; 2021 May; 24(3):611-623. PubMed ID: 33611641
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
[TBL] [Abstract][Full Text] [Related]
16. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
Front Immunol; 2019; 10():835. PubMed ID: 31134049
[No Abstract] [Full Text] [Related]
17. Emerging immune checkpoints for cancer therapy.
Li X; Hu W; Zheng X; Zhang C; Du P; Zheng Z; Yang Y; Wu J; Ji M; Jiang J; Wu C
Acta Oncol; 2015 Nov; 54(10):1706-13. PubMed ID: 26361073
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
